Trial Profile
Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; Diagnostic use
- 22 Mar 2019 Status changed from not yet recruiting to discontinued.
- 22 May 2018 Planned initiation date changed from 1 Nov 2017 to 1 Aug 2018.
- 02 Nov 2017 Planned initiation date changed from 15 Mar 2017 to 1 Nov 2017.